First Parkinson’s drug to treat hallucinations and delusions is approved

News

Author: AdminPublished: 6 May 2016

Prep: Cook: Serves:

A new antipsychotic drug to treat symptoms of psychosis associated with Parkinson’s disease like hallucinations and delusions has become the first to be approved by the FDA.

The drug, called Nuplazid (pimavanserin), is the first of its kind on the market for use by people living with Parkinson’s in the US. It works only on the serotonin system, meaning – unlike previous antipsychotic medication – it doesn’t worsen motor symptoms.

It is estimated that around half the people with the condition may at some point experience hallucinations (seeing things that aren’t there) or delusions (holding false, paranoid, beliefs), also referred to as psychosis.

Dr Mitchell Mathis, director of the Division of Psychiatry Products in the FDA’s Center for Drug Evaluation and Research, said: “Nuplazid represents an important treatment for people with Parkinson’s.”

Nuplazid is developed by Acadia Pharmaceuticals and will be available from June 2016 at the estimated annual cost of US$23,400.

Last Month

Next Month

Go Back

Share this story

Comments

Advances

EU approval for Medtronic DBS systems improves access to full-body MRI scans

Patients receiving DBS therapy have the option of full-body MRI scans

“The beginning of a wonderful collaboration between countries, organisations and people”

The EPDA hosted a two-day event last week

How virtual reality is giving Parkinson’s patients a ‘disease-free’ Second Life

Second Life: a (virtual) world without Parkinson’s

Can tremor predict the effect of Parkinson’s disease medication?

Researchers from the Netherlands have found a link between tremor symptoms and how dopaminergic medication impacts learning abilities in Parkinson’s disease. Many people with Parkinson’s become sensitive to learning through rewards due to a decrease in dopamine in the brain. As part of a new study – published in the scientific journal Brain –researchers assessed 43 tremor-dominant and 20 non-tremor dominant people with Parkinson’s while they were on and off dopaminergic medication. The results showed that in people with Parkinson’s who do not experience tremor, dopaminergic medication improves the ability to learn from rewards – and in those with tremor, the medication has no impact on reward learning. Rick Helmich, co-author of the study and a neurologist at Radboud University Medical Centre, the Netherlands, said: “Whether someone experiences tremor or not might therefore potentially have a significant predictive value regarding the effectiveness of medication in the cognitive domain. However, more…

Could a ‘Mediterranean diet’ lower the risk of Parkinson’s for women?

A study by scientists in Sweden has suggested that women who eat a ‘Mediterranean diet’ at middle age could have a lower risk of Parkinson’s later in life. The report, published in the Movement Disorders journal, used dietary information from more than 47,000 women aged 29 to 49, recorded between the early 1990s and 2012. They looked at how closely the women adhered to a Mediterranean dietary pattern (MDP), which is high in foods such as vegetables, fruits, nuts, unsaturated fats and legumes. They then compared the information with data from the Swedish National Patient Register to find out whether participants had been diagnosed with Parkinson’s. The researchers found that those with a high adherence to the diet had a 46% lower risk of being diagnosed with the condition compared to those with a low adherence, concluding that “higher adherence to a Mediterranean diet at middle age was associated with…

Pesticide that increases Parkinson’s risk by 150% reapproved in the US

The US Environmental Protection Agency (EPA) has allowed the continued use of paraquat, a pesticide that increases the risk of Parkinson’s disease by 150%. The pesticide – which has already been banned in 32 countries – was reapproved by the EPA in October as part of a review of the safety of all herbicides and pesticides in the US, a process which takes place every 15 years. Many studies have shown that as well as increased risk of Parkinson’s disease, exposure to the pesticide is associated with other health issues and risk of death. Exposure to paraquat endangers both the farmers who use the pesticide, as well as the families who can be exposed to it through the air or transfers onto clothing or other materials. In response to the reapproval, the Michael J Fox Foundation is calling on the Parkinson’s community to ask senators and representatives to support a…

All fields required

First name*
Last name*
Email address*
Enter Email Confirm Email
Country of residence*
About me*
- I have Parkinson's disease
- I am a partner / carer / family / friend of someone who has Parkinson's
- I am a healthcare professional with an interest in Parkinson's
- I work for a Parkinson's disease organisation
- Other
CAPTCHA
*
- By proceeding you agree to our
Email
This field is for validation purposes and should be left unchanged.

First Parkinson’s drug to treat hallucinations and delusions is approved

News

Author: AdminPublished: 6 May 2016

Prep: Cook: Serves:

Last Month

Next Month

Share this story

Comments

sponsored article

Advances

EU approval for Medtronic DBS systems improves access to full-body MRI scans

Europe

“The beginning of a wonderful collaboration between countries, organisations and people”

Special reports

How virtual reality is giving Parkinson’s patients a ‘disease-free’ Second Life

Can tremor predict the effect of Parkinson’s disease medication?

Could a ‘Mediterranean diet’ lower the risk of Parkinson’s for women?

Pesticide that increases Parkinson’s risk by 150% reapproved in the US

{title}

Subscribe

First Parkinson’s drug to treat hallucinations and delusions is approved

News

Author: AdminPublished: 6 May 2016

Prep: Cook: Serves:

Last Month

Next Month

Share this story

Comments

Related articles

sponsored article

Advances

EU approval for Medtronic DBS systems improves access to full-body MRI scans

Europe

“The beginning of a wonderful collaboration between countries, organisations and people”

Special reports

How virtual reality is giving Parkinson’s patients a ‘disease-free’ Second Life

Can tremor predict the effect of Parkinson’s disease medication?

Could a ‘Mediterranean diet’ lower the risk of Parkinson’s for women?

Pesticide that increases Parkinson’s risk by 150% reapproved in the US

{title}

Subscribe

Sign in